Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2‐Positive Breast Cancer and Other Solid Tumors

Trastuzumab deruxtecan (DS‐8201) is a human epidermal growth factor receptor 2 (HER2)–targeting antibody–drug conjugate with a novel enzyme‐cleavable linker, a topoisomerase I inhibitor payload, and a drug‐to‐antibody ratio of ≈ 8. We have characterized the population pharmacokinetics (PK) of trastu...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Ophelia, Xiong, Yuan, Endo, Seiko, Yoshihara, Kazutaka, Garimella, Tushar, AbuTarif, Malaz, Wada, Russ, LaCreta, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246728/
https://www.ncbi.nlm.nih.gov/pubmed/33118153
http://dx.doi.org/10.1002/cpt.2096

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246728/
https://www.ncbi.nlm.nih.gov/pubmed/33118153
http://dx.doi.org/10.1002/cpt.2096

Ejemplares similares